Clinical and marketed proteasome inhibitors for cancer treatment

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The ubiquitin-proteasome pathway (UPP) is a primary cellular mechanism for protein degradation, regulating vital processes like cell growth, apoptosis, and immune responses.
• The proteasome acts as a critical gatekeeper within the UPP, controlling protein turnover.
• A strong link between proteasome dysfunction and cancer development has emerged, highlighting proteasome inhibitors as a promising therapeutic strategy.

Purpose of the Study:

• To review the historical development of drugs targeting the 20S proteasome.
• To analyze the structure-activity relationships (SARs) of various proteasome inhibitors.
• To summarize the status of completed and ongoing clinical trials for proteasome-targeting cancer therapies.

Main Methods:

• Literature review of drug development targeting the 20S proteasome.
• Analysis of structure-activity relationships for proteasome inhibitors.
• Compilation and summary of clinical trial data for proteasome inhibitors.

Main Results:

• Several small molecular proteasome inhibitors have been developed, with bortezomib and carfilzomib approved for clinical use.
• Ongoing research is exploring novel proteasome inhibitors with varied structures and potencies.
• Numerous clinical trials are evaluating the efficacy and safety of these inhibitors in cancer treatment.

Conclusions:

• Proteasome inhibitors represent a significant advancement in cancer therapy.
• Understanding SARs is key to designing more effective and specific proteasome inhibitors.
• Continued clinical investigation is essential to optimize the use of proteasome inhibitors in oncology.